NVS Novartis AG
- 99.680
- -0.850-0.85%
Novartis AG News
Travere Gains on Novartis Data for Filspari Rival, Calliditas Buyout
Press Release: Dr. Patrice Matchaba Appointed as Chief Executive Officer of the Bill & Melinda Gates Medical Research Institute
Dr. Patrice Matchaba Appointed as Chief Executive Officer of the Bill & Melinda Gates Medical Research Institute PR Newswire CAMBRIDGE, Mass., May 28, 2024 CAMBRIDGE, Mass., May 28, 2024 /PRNewswir
Novartis Reports Phase 3 Results for IgA Nephropathy Treatment
Reported Saturday, Novartis' Latest Phase III Data For Fabhalta (Iptacopan) In C3 Glomerulopathy (C3G) A Significant 35.1% Reduction In Proteinuria Compared To Placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical
Reported Saturday, Novartis' Phase III Data For Atrasentan Shows Reduction In Proteinuria, Enhancing The Company's IgA Nephropathy (Igan) Portfolio
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
Novartis Reports Positive Results From Phase 3 Study of Investigational Chronic Kidney Disease Drug
Novartis' (NOVN.SW) investigational oral selective endothelin A receptor antagonist reduced more proteinuria in patients with the chronic kidney disease IgA nephropathy than placebo treatment, according to a May 25 release.
Novartis Atrasentan Phase III Data Show Clinically Meaningful Proteinuria Reduction Further Advancing Company's IgA Nephropathy (IgAN) Portfolio
Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN)1.
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
U.S. drug wholesaler Cencora Inc (NYSE:COR), formerly AmerisourceBergen, is notifying affected individuals about their personal and highly sensitive medical information stolen during a cyberattack ear
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating
Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating.
Express News | Novartis AG : Berenberg Raises Target Price to $85 From $83
Form 144 | Novartis AG(NVS.US) Officer Proposes to Sell 254.83K in Common Stocks
SEC FILLINGS DISCLOSED/ May 22, $Novartis AG(NVS.US)$、$NOVARTIS AG(NVSEF.US)$ Officer Gal Aharon intends to sell 2,500 shares of its common stock on May 22, with a total market value of approximately
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Europe's Q1 earnings season ends: profits fell 6%, and “barely qualified” banks and pharmaceutical giants supported half of the country
The Zhitong Finance App learned that the strong performance of European banks and pharmaceutical giants helped push European companies' profits unexpectedly in the first quarter to exceed market expectations. Analysts believe that this also indicates that future performance guidelines may be further raised. According to Bloomberg Intelligence data, finance and healthcare are the only segments of the MSCI European Index with profitable growth, which is better than the decline in market expectations. Overall, the profit decline of 6% in the MSCI Europe Index (almost all constituent stocks reported results) was better than the general forecast of 11%. Bloomberg I
Express News | NYSE Order Imbalance 74976.0 Shares on Sell Side
MorphoSys Gains After Novartis Discloses All Tender Offer Conditions Were Met
Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
New York, USA, May 16, 2024 (GLOBE NEWSWIRE) -- Motor Neuron Disease Clinical Trial Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight The
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE:PFE) and AstraZeneca Plc (NASDAQ:AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, j
Novartis Takeover Bid for MorphoSys Tops Minimum Acceptance Threshold
Novartis' (NOVN.SW) takeover offer surpassed the 65% minimum threshold as it was accepted by 79.6% of MorphoSys shareholders.
Analysis
Price Target
No Data
